ELAN vs NEOG vs COR Stock Comparison

Elanco Animal Health, Neogen and Cencora Prices as of Nov 13, 2026 Peers: Industry group
NEOG Neogen Corp
$11.23 -7.4% 1M +76.3% 1Y
Market cap
$2.37B
P/E
–
Revenue (TTM)
$883.99M
Div. yield
–
Diagnostic Equipment Healthcare
1 win
COR Cencora, Inc.
$359.02 +6.8% 1M -1.8% 1Y
Market cap
$69.10B
P/E
22.6x
Revenue (TTM)
$337.40B
Div. yield
–
Drug Distribution Healthcare
4 wins

Head to Head

10 decided of 12

Elanco Animal Health leads on 5 of the 12 questions below (Elanco Animal Health 5, Cencora 4, Neogen 1). Which ones matter depends on what you are buying for; a cheap multiple and slow growth often come together.

QuestionELANNEOGCORLeader
Larger companyMarket capitalisation $13.25B $2.37B $69.10B COR
Cheaper on earningsLower P/E, profitable companies only -90.2x -42.3x 22.6x –
Cheaper on forward earningsLower price / next fiscal year consensus EPS 23.7x 35.1x 18.8x COR
Faster revenue growthRevenue growth, trailing twelve months +12.1% -0.3% +5.0% ELAN
More profitableNet margin, trailing twelve months -2.9% -6.3% — ELAN
Better return on capitalReturn on invested capital 6.9% -0.2% — ELAN
Less leveragedLower net debt / EBITDA 2.3x 5.4x — ELAN
Higher dividend yieldTrailing dividend yield 0.00% 0.00% 0.00% –
Better 1-year returnPrice return, last 12 months +21.8% +76.3% -1.8% NEOG
Better 5-year returnAnnualised price return, 5 years -4.1%/yr -24.0%/yr +23.4%/yr COR
Less volatileAnnualised volatility, 1 year 43.4% 55.6% 33.4% COR
Higher overall scoreMean of the five percentile scores vs peers 69/100 58/100 56/100 ELAN

Percentile Scorecard

ELANNEOGCOR

Each axis is the mean percentile of its metrics against the company's industry group. 100 is the best in the group, 50 the middle.

Scores by Axis

AxisELANNEOGCOR
Valuation 92 #52 of 660 72 #68 of 243 54 #13 of 27
Growth 67 #208 of 619 49 #117 of 228 64 #10 of 26
Profitability 85 #90 of 595 63 #83 of 222 64 #10 of 26
Financial Health 31 #473 of 683 47 #132 of 248 –
Shareholder Returns 73 #126 of 459 61 #63 of 158 41 #11 of 18
Overall 69 58 56
  • ELAN ranked among 695 companies in Pharmaceuticals and Biotechnology
  • NEOG ranked among 252 companies in Medical Devices and Diagnostics
  • COR ranked among 27 companies in Healthcare Payers and Distributors

Price Performance

Price return, split-adjusted, before dividends. Click a name to hide or show it.

Returns

PeriodELANNEOGCORSPY
1 month +18.8%-7.4%+6.8% -2.0%
3 months +13.2%-3.6%+14.4% -2.8%
6 months +34.9%+37.1%+39.3% +2.0%
Year to date +18.4%+60.7%+6.3% +10.6%
1 year +21.8%+76.3%-1.8% +12.2%
3 years +136.2%-29.4%+84.7% +68.1%
3 years, per year +33.2%-11.0%+22.7% +18.9%
5 years -18.9%-74.6%+186.4% +61.4%
5 years, per year -4.1%-24.0%+23.4% +10.1%
10 years —-51.3%+354.9% +248.5%
10 years, per year —-6.9%+16.4% +13.3%

Risk

MeasureELANNEOGCORSPY
Volatility, 1Y 43.4%55.6%33.4% 13.6%
Downside volatility, 1Y 43.7%47.7%40.0% 13.9%
Beta vs S&P 500, 1Y 1.321.420.05 1.00
Return / volatility, 1Y 0.501.37-0.05 0.90
Max drawdown, 5Y -75.0%-90.6%-32.6% -25.4%
From 52-week high -0.2%-19.7%-4.2% -3.2%
52-week high $26.84$13.98$374.75 $779.14
52-week low $19.80$5.41$252.74 $631.97

Valuation History

Weekly multiples on trailing twelve-month fundamentals. Negative or extreme readings (a loss year, a collapsed denominator) are left out so the chart stays readable.

MultipleELANNEOGCOR
P/E now vs peer median -91.1xmedian 17.0x -43.7xmedian 26.5x 22.6xmedian 25.2x
P/S now vs peer median 2.6xmedian 8.4x 2.8xmedian 2.7x 0.2xmedian 0.4x
EV/EBITDA now vs peer median 11.8xmedian 14.6x 27.5xmedian 18.4x —median 14.5x
P/FCF now vs peer median 32.8xmedian 19.0x 49.2xmedian 25.4x 14.5xmedian 16.5x
P/B now vs peer median 2.0xmedian 2.0x 1.2xmedian 2.5x 18.6xmedian 2.7x
PEG now vs peer median -1.82median 0.43 1.06median 0.98 —median 1.72

Financial History

Reported figures by fiscal period, placed on the calendar year (or quarter) each period ended in, so companies with different fiscal years line up.

Trailing twelve monthsELANNEOGCOR
Revenue $5.15B $883.99M $337.40B
Gross profit $2.89B $418.98M $13.87B
Operating income $720.00M -$7.38M $3.93B
Net income -$147.00M -$56.10M $3.51B
Free cash flow $408.00M $49.80M –
R&D $381.00M $19.76M –
EPS (diluted) $-0.29 $-0.26 –
Cash & equivalents $465.00M $172.00M $4.88B
Total debt $3.71B $774.20M –
Shares (diluted) 506.50M 218.10M 193.94M
Enterprise value $11.29B $1.71B $69.10B

All Metrics

58 metrics · best in bold

Bold marks the best reading: the lowest positive value for multiples, leverage and payout, the highest for everything else. The bar under each value is its percentile against that company's own peers. Hover a value for its rank and the peer median.

Valuation

12 metrics
MetricELANNEOGCOR
P/E -91.1x -43.7x 22.6x
P/FCF 32.8x 49.2x 14.5x
P/Operating cash flow 21.8x 28.7x 14.3x
P/S 2.6x 2.8x 0.2x
P/B 2.0x 1.2x 18.6x
P/Tangible book 3.7x 3.1x 18.6x
EV/EBITDA 11.8x 27.5x –
EV/EBIT 23.1x -413.9x –
EV/Revenue 3.2x 3.5x 0.2x
EV/FCF 40.8x 61.3x –
EV/Operating cash flow 27.1x 35.8x 14.3x
PEG (3Y EPS CAGR) -1.82 1.06 –

Growth

14 metrics
MetricELANNEOGCOR
Revenue growth (1Y) 12.1% -0.3% 5.0%
Revenue CAGR (3Y) 5.6% -1.3% 8.8%
Gross profit growth (1Y) 14.6% 1.8% 20.8%
Gross profit CAGR (3Y) 4.9% -3.1% 15.7%
Operating income growth (1Y) 20.6% 99.3% 49.5%
Operating income CAGR (3Y) 41.2% -29.0% 18.9%
Net income growth (1Y) -508.3% 94.6% 124.0%
Net income CAGR (3Y) 49.5% -28.3% 26.3%
EPS growth (1Y) -500.5% 94.6% –
EPS CAGR (3Y) 50.0% -41.1% –
Operating cash flow growth (1Y) -2.4% -1.9% 23.6%
Operating cash flow CAGR (3Y) 69.1% 2.9% 7.0%
Free cash flow growth (1Y) 10.9% 1,631% –
Free cash flow CAGR (3Y) 117.8% 126.1% –

Profitability

14 metrics
MetricELANNEOGCOR
Gross margin 56.2% 47.4% –
EBITDA margin 27.5% 12.5% –
Operating margin 14.0% -0.8% –
Pretax margin -1.8% -7.7% –
Net margin -2.9% -6.3% –
FCF margin 7.9% 5.6% –
Operating cash flow margin 11.9% 9.6% 1.4%
Return on equity -2.2% -2.7% 101.2%
Return on assets -1.1% -1.7% 4.1%
Return on invested capital 6.9% -0.2% –
Return on capital employed 6.2% -0.2% –
Asset turnover 0.4x 0.3x 3.9x
Cash conversion (OCF / net income) -4.2x -1.5x 1.4x
Stock comp / revenue 1.5% 1.3% –

Financial Health

11 metrics
MetricELANNEOGCOR
Debt / assets 27.8% 23.4% –
Debt / equity 0.6x 0.4x –
Net debt / EBITDA 2.3x 5.4x –
Debt / FCF 9.1x 15.5x –
Liabilities / assets 50.3% 36.8% –
Equity / assets 49.7% 63.2% 4.2%
Interest coverage 2.8x – –
Current ratio 2.1x 3.9x 0.9x
Quick ratio 0.9x 2.1x –
Cash ratio 0.3x 1.2x –
Altman Z-score 1.72 1.39 –

Shareholder Returns

7 metrics
MetricELANNEOGCOR
Dividend yield – – 0.9%
Net buyback yield -0.3% -0.1% –
Shareholder yield -0.3% -0.1% 0.9%
Payout ratio (earnings) – – –
Payout ratio (FCF) – – –
Dividend growth (1Y) – – –
Dividend CAGR (3Y) – – –

Analyst Estimates

Solid lines are reported fiscal-year results; dashed lines are the consensus for the years ahead. Hover a year for the analysts' high and low, and how each result compared with its estimate.

ConsensusELANNEOGCOR
Forward P/E 23.7xFY2026 35.1xFY2026 18.8xFY2027
EPS, next fiscal year $1.13FY2026 $0.32FY2026 $19.07FY2027
EPS growth, next FY +20.2%FY2026 0.0%FY2026 +6.1%FY2027
EPS growth, the year after +22.1% +31.3% +17.4%
Revenue, next fiscal year $4.82BFY2026 $847.28MFY2026 $328.27BFY2027
Revenue growth, next FY +2.4%FY2026 -2.7%FY2026 -2.7%FY2027
Revenue growth, the year after +19.4% -1.5% +19.1%

Institutional Ownership

13F filings, quarter ended Jun 30, 2026
HoldersELANNEOGCOR
Held by institutions 100.0% 100.0% 94.7%
Institutions holding 526 315 1,345
Change in shares held, QoQ +4.4% +1.6% +15.7%
Institutions buying 246 150 542
Institutions selling 211 106 612
Buyers to sellers 1.17 1.42 0.89

Return Correlation

Daily returns, last 12 months

1.00 means two stocks move in lockstep, 0 that they move independently. Pairs below about 0.5 diversify each other.

ELANNEOGCOR
ELAN 1.00 0.28 -0.03
NEOG 0.28 1.00 -0.03
COR -0.03 -0.03 1.00

Add a Peer

Largest companies in the same industry

Related Comparisons

Frequently Asked Questions

Which is bigger, ELAN, NEOG and COR?

Cencora (COR) is the largest by market capitalisation: Elanco Animal Health (ELAN) $13.25B, Neogen (NEOG) $2.37B, Cencora (COR) $69.10B.

Which company is growing faster?

Elanco Animal Health (ELAN) grew revenue fastest over the trailing twelve months: Elanco Animal Health (ELAN) +12.1%, Neogen (NEOG) -0.3%, Cencora (COR) +5.0%.

Which company is more profitable?

Elanco Animal Health (ELAN) has the highest net margin (Elanco Animal Health (ELAN) -2.9%, Neogen (NEOG) -6.3%). On return on invested capital, Elanco Animal Health (ELAN) leads (Elanco Animal Health (ELAN) 6.9%, Neogen (NEOG) -0.2%).

Which stock has performed better?

Over the past year Neogen (NEOG) returned the most: Elanco Animal Health (ELAN) +21.8%, Neogen (NEOG) +76.3%, Cencora (COR) -1.8%. Over five years, Cencora (COR) compounded fastest (Elanco Animal Health (ELAN) -4.1%/yr, Neogen (NEOG) -24.0%/yr, Cencora (COR) +23.4%/yr). Returns are price only, before dividends.

Which stock is riskier?

By one-year price volatility, Cencora (COR) has been the steadiest (Elanco Animal Health (ELAN) 43.4%, Neogen (NEOG) 55.6%, Cencora (COR) 33.4%). Volatility measures how widely the price swings, not the risk of the business.

Which is the better stock, ELAN, NEOG and COR?

There is no single answer; it depends on what you are buying for. On the 12 head-to-head measures on this page, Elanco Animal Health (ELAN) leads on 5. Business Quant does not give investment advice; use the comparison as a starting point for your own research.

Data from SEC filings, exchange prices and consensus estimates, via Business Quant. Percentile scores compare each company with its own peer group, so two companies' scores are each relative to different peers unless you rank against the whole market. Price returns exclude dividends. Nothing on this page is investment advice.